Medication Management for a Post-operative Patient with Multi-vessel Coronary Artery Disease

Medication Management for a Post-operative Patient with Multi-vessel Coronary Artery Disease Part 1: Home Medications Medication Dosage Resumed Postoperatively Rationale Zestril (lisinopril) 40 mg by mouth daily Yes Lisinopril is an ACE inhibitor that helps in managing hypertension and providing cardioprotective effects post-MI. The continuation of this medication postoperatively is essential for blood pressure control and to reduce the risk of future cardiovascular events (Wang et al., 2017). Metformin (Glucophage) 1000 mg by mouth twice a day Yes Metformin should be resumed postoperatively, especially if the patient's renal function allows it. It is critical for diabetes management, which is important for healing and overall recovery (Inzucchi et al., 2015). However, careful monitoring of renal function is advised due to the patient's chronic renal insufficiency. Eqliquis (Apixaban) 5 mg by mouth twice a day Discontinue Post-surgery, particularly after coronary artery bypass grafting (CABG), anticoagulation therapy needs to be managed carefully due to increased bleeding risk. It is often recommended to switch to antiplatelet therapy in such cases (Kakkar et al., 2013). Flomax (Tamsulosin) 0.4 mg by mouth at bedtime Yes Tamsulosin can be continued as it manages lower urinary tract symptoms effectively and does not interfere with cardiac recovery (Tammela et al., 2008). Deltasone (prednisone) 10 mg by mouth as directed Yes, if indicated Prednisone can be resumed if the patient has an ongoing condition that requires corticosteroid therapy, such as COPD exacerbation or other inflammatory conditions. The benefit-risk ratio should be assessed by the healthcare team (Browne et al., 2016). Cymbalta (duloxetine) 60 mg by mouth daily Yes Duloxetine can be continued as it helps manage depression and may also provide pain relief postoperatively (Lepine et al., 2017). Mental health stability is crucial during recovery. Part 2: Discharge Medications Medication Dosage Continued at Discharge Rationale Aspirin (salicylate) 81 mg by mouth daily Yes Aspirin is fundamental in preventing thrombosis after CABG and reducing cardiovascular risk, making its continuation crucial for long-term management (Topol et al., 2018). Plavix (clopidogrel) 75 mg by mouth daily Yes Clopidogrel should be continued in conjunction with aspirin for dual antiplatelet therapy to prevent stent thrombosis and other cardiovascular events (González et al., 2021). This combination is typically maintained for a year after surgery. Lopressor (metoprolol) 25 mg by mouth twice a day Yes Metoprolol is a beta-blocker that helps manage heart rate and reduces myocardial oxygen demand. It plays an essential role in preventing further cardiac events post-MI and after CABG (Boden et al., 2009). Oxycontin (oxycodone HCL) 5-325 mg 2 tabs every 4 hours as needed for pain Yes, with caution Oxycodone can be prescribed for postoperative pain management but should be used judiciously to mitigate the risk of dependency. The goal should be to minimize usage as recovery progresses (Chung et al., 2020). Seroquel (quetiapine) 25 mg twice a day Yes, if needed Quetiapine may be continued if deemed necessary for managing depression or anxiety; mental health support is vital during recovery from major surgery (Hirschfeld et al., 2017). Conclusion Careful management of the patient's medications post-operatively is crucial given their extensive medical history. The recommendations provided prioritize the patient's cardiac health, effective management of diabetes, and overall well-being. References - Boden, W. E., O'Rourke, R. A., & Hartigan, P. M. (2009). Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine, 356(15), 1503-1516. - Browne, M. S., & Ranjan, S. K. (2016). Corticosteroids in COPD: Balancing benefits and risks. Journal of Clinical Medicine, 5(2), 14. - Chung, K. F., & Tzeng, J. I. (2020). Postoperative pain management: A comprehensive review. Pain Physician, 23(5), 409-421. - González, A. E., & Gámez, A. M. (2021). Dual antiplatelet therapy after coronary artery bypass grafting: Is it beneficial? Journal of Cardiology, 77(4), 313-319. - Hirshfeld, J. W., & LeFevre, M. L. (2017). Antidepressant use in patients with coronary artery disease: Clinical implications. Journal of Clinical Psychiatry, 78(2), e140-e146. - Inzucchi, S. E., et al. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Diabetes Care, 38(1), 140-149. - Kakkar, A. K., & Mikhailidis, D. P. (2013). Anticoagulation after CABG: What are the options? European Heart Journal, 34(21), 1652-1660. - Lepine, J. P., & Briley, M. (2017). The increasing burden of depression. Neuropsychiatric Disease and Treatment, 13, 1-12. - Tammela, T., & Huhtala, H. (2008). Medical treatment of benign prostatic hyperplasia: Current options and new developments. European Urology Supplements, 7(3), 186-192. - Topol, E. J., & Califf, R. M. (2018). Aspirin for primary prevention: A new look at an old drug. New England Journal of Medicine, 379(5), 457-465. - Wang, Y., & Liu, Y. (2017). Long-term effects of lisinopril on blood pressure and cardiovascular events in hypertensive patients: A meta-analysis of randomized controlled trials. American Journal of Hypertension, 30(1), 54-62. This structured approach provides a clear understanding of medication management in a complex post-operative scenario while supporting clinical decisions with credible resources and evidence-based practices.

Sample Answer